Liontrust Investment Partners’s iRadimed IRMD Stock Holding History

Liontrust Investment Partners’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.05M	Sell	21,255 -15,216	-42%	-$1.52M	0.03%	147
2025 Q4	$3.55M	Sell	36,471 -1,315	-3%	-$113K	0.05%	147
2025 Q3	$2.69M	Sell	37,786 -1,168	-3%	-$77.8K	0.04%	142
2025 Q2	$2.33M	Sell	38,954 -1,467	-4%	-$80.4K	0.03%	151
2025 Q1	$2.12M	Sell	40,421 -28,783	-42%	-$1.62M	0.03%	147
2024 Q4	$3.81M	Buy	69,204 +4,808	+7%	+$253K	0.06%	128
2024 Q3	$2.83M	Hold	64,396	–	–	0.04%	137
2024 Q2	$2.83M	Buy	+64,396	New	+$2.74M	0.04%	137

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Liontrust Investment Partners's IRMD Position: Q1 2026 in Review

Liontrust Investment Partners reduced its iRadimed (IRMD) stake by 42% in Q1 2026, selling an estimated $1.52M and leaving 21,255 shares worth $2.05M. The position accounts for 0.03% of the portfolio, ranked #147.

Liontrust Investment Partners first reported a position in IRMD in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.81M in Q4 2024. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Liontrust Investment Partners held 21,255 shares of iRadimed worth $2.05M as of Q1 2026.
Liontrust Investment Partners sold 15,216 iRadimed shares in Q1 2026, an estimated $1.52M.
iRadimed made up 0.03% of Liontrust Investment Partners's portfolio in Q1 2026, its #147 holding.
Liontrust Investment Partners first reported a position in iRadimed in Q2 2024 and has held it in 8 quarters since.
Liontrust Investment Partners's iRadimed position peaked at $3.81M in Q4 2024.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Liontrust Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.